Shlomit Schaal to Vascular Endothelial Growth Factor A
This is a "connection" page, showing publications Shlomit Schaal has written about Vascular Endothelial Growth Factor A.
Connection Strength
0.719
-
Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008 Dec; 115(12):2199-205.
Score: 0.273
-
Schaal S, Sherman MP, Nesmith B, Barak Y. UNTREATED OBSTRUCTIVE SLEEP APNEA HINDERS RESPONSE TO BEVACIZUMAB IN AGE-RELATED MACULAR DEGENERATION. Retina. 2016 Apr; 36(4):791-7.
Score: 0.115
-
Ozkok A, Saleh OA, Sigford DK, Heroman JW, Schaal S. THE OMAR STUDY: Comparison of Ozurdex and Triamcinolone Acetonide for Refractory Cystoid Macular Edema in Retinal Vein Occlusion. Retina. 2015 Jul; 35(7):1393-400.
Score: 0.109
-
Nesmith BL, Ihnen M, Schaal S. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea. Retina. 2014 Dec; 34(12):2423-30.
Score: 0.104
-
Rifkin L, Schaal S. Shortening ocular pain duration following intravitreal injections. Eur J Ophthalmol. 2012 Nov-Dec; 22(6):1008-12.
Score: 0.087
-
Toledano S, Lu H, Palacio A, Ziv K, Kessler O, Schaal S, Neufeld G, Barak Y. A Sema3C Mutant Resistant to Cleavage by Furin (FR-Sema3C) Inhibits Choroidal Neovascularization. PLoS One. 2016; 11(12):e0168122.
Score: 0.030